Dual‑drug therapy forces leukemia cells to exhaust energy in mouse study

Researchers at the University of Gothenburg have developed a novel therapeutic strategy for leukemia that exploits a paradoxical metabolic approach. By simultaneously stimulating and inhibiting key signaling pathways, the new drug forces malignant cells to continue proliferating despite lacking the energy required to sustain their growth. This “push‑and‑brake” method, described in a recent preclinical study, represents a departure from conventional chemotherapy, which typically relies on a single target or pathway.

In the first animal trials, the drug was administered to mice bearing human leukemia cells. The treated animals exhibited a marked reduction in tumor burden and an extended survival rate compared with controls. Molecular analyses indicated that the compound induced a metabolic crisis in the cancer cells, compelling them to expend resources at an unsustainable rate. While the study was limited to a murine model, the results suggest that the approach could selectively target leukemia cells while sparing normal tissues.

The research team plans to advance the compound into further preclinical testing and eventually human trials. If the findings translate to patients, this strategy could offer a new avenue for treating leukemias that are resistant to existing therapies. The University of Gothenburg’s work underscores the potential of metabolic manipulation in oncology and highlights the importance of innovative approaches to drug development.